RESEARCH ARTICLE

Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats

Nabil Mohie Abdel-Hamid¹, Ahmed Wahid^{2*}, Maiiada Hassan Nazmy², Marwa Abdel-Moniem Eisa²

Abstract

Background: Complementary and alternative medicine has been highly appreciated as a supportive regimen for classical treatment strategies. Here we offer a nutrition-based adjuvant therapy for liver fibrosis, a major risk factor for cirrhosis and hepatocellular carcinoma. **Aim of the study:** To evaluate the possible hepatoprotective effects of Jerusalem artichoke tubers (JAT) in combination with interferon and ribavirin. **Materials and Methods:** Twelve groups of rats were administered JAT, interferon and ribavirin either separately or in combination from day one of CCL₄ administration until the end of the study. Animals were killed after 8 weeks of CCL₄-induced hepatotoxicity. **Results:** Hepatocytes from rats treated with triple combination of interferon, ribavirin, and JAT showed more less normal architecture compared to CCL₄-treated rats. We also detected significantly higher hepatic protein expression levels of p53, BAX and transforming growth factor- β (TGF- β) in the CCL₄-intoxicated group compared to normal controls, as evidenced by immunohistochemical staining and western blotting analyses. Addition of JAT as a supportive regimen improved response to ribavirin and interferon and effectively participated in retaining normal histopathological and biochemical criteria and significantly lowered protein expression of p53, BAX, and TGF- β . **Conclusions:** We suggest that addition of JAT as a supportive regimen to interferon and ribavirin effectively potentiates their anti-fibrotic effects.

Keywords: Jerusalem artichoke tubers - rat liver model - fibrosis - p53 - BAX - TGF- β

Asian Pac J Cancer Prev, 17 (4), 1979-1985

Introduction

Repeated liver damage over a relatively long period can cause chronic liver injury which usually results in a healing response that finally replaces the normal liver architecture in the form of fibrosis or cirrhosis (Minano and Garcia-Tsao, 2010). Amongst the factors that can lead to liver fibrosis are toxins and drugs (Aithal et al., 2011; Gao and Bataller, 2011), metabolic disorders (Nobili et al., 2011), autoimmune-related diseases (Mayo, 2011), and viral infections (Thursz et al., 2011).

Interferons are endogenous proteins produced by a variety of cells following to viral infection. It has been long used for patients with hepatitis C virus infection together with ribavirin (Fujii et al., 2015; Veillon et al., 2015).

Complementary and alternative medicine has been highly appreciated as a supportive regimen for classical treatment strategies. Identification of a hepatoprotective agents derived from natural sources is an urgent necessity. Indeed, herbs have been used as a remedy for various diseases (Abdel-Hamid et al., 2011). Recently, it has been proposed that some medicinal plant extracts have potential

antifibrotic effects (Schuppan et al., 1999; Gebhardt, 2002) such as silymarin (Boigk et al., 1997) and Inchin-ko-to (TJ-135) (Sakaida et al., 2003).

Here we offer a nutrition-based adjuvant therapy for liver fibrosis, a major risk factor for cirrhosis and hepatocellular carcinoma. Jerusalem Artichoke Tubers (JAT) (*Helianthus tuberosus* L.) is a species of sunflower, native plant to the North American plains cultivated for different purposes in many countries. The plant was brought to Europe by the French explorer Samuel de Champlain. It has other names like, sunroot, sunchoke, or earth apple. It can be eaten both raw and cooked. It was reported to have potential anti-diabetic and anti-oxidant effects but little is known about possible mechanisms by which it exerts these effects (Zawistowski et al., 1986; Chang et al., 2014; Punzi et al., 2014). The root contains dietary fibers, antioxidants, in addition to small proportions of minerals, and vitamins (Roberfroid and Delzenne, 1998; Roberfroid et al., 1998). It is one of the finest sources for dietary fibers which are reported to decrease serum cholesterol and low density lipoproteins. JAT is rich in oligo-fructose inulin, which is a soluble,

¹Biochemistry Department, Faculty of Pharmacy, Kafr-El-Sheikh University, ²Biochemistry Department, Faculty of Pharmacy, Minia University, Minya, Egypt *For correspondence: ahmed_wahid@mu.edu.eg

zero calorie, non-starch polysaccharide and since it does not metabolize inside the human body, JAT is considered an ideal sweetener for diabetics. Moreover, it was also reported that JAT contains minor amounts of anti-oxidant vitamins such as vitamin C, and other flavonoid containing compounds which together help scavenge harmful free radicals, and therefore protect against liver inflammation (Kucukgergin et al., 2010; Serni et al., 2013).

We noticed that most studies focused on role of JAT against diabetes mellitus or it's hepatic manifestation, non-alcoholic fatty liver diseases. No previous study tested its hepatoprotective effect in a CCL₄ fibrosis model. Our preliminary study (Abdel-Hamid et al., 2015) showed that JAT ameliorated CCL₄-induced hepatotoxicity in rats. Here, we suggest that addition of JAT to the standard interferon-ribavirin anti-fibrotic regimen may effectively improve their curative potential.

Materials and Methods

Chemicals and kits

Diagnostic kits for serum alanine aminotransferase (ALT) and aspartate amino transferase (AST) were purchased from Biodiagnostic CO., Egypt. Diagnostic kit for bilirubin was purchased from Randox Laboratories Co., UK. Carbon tetrachloride was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Interferon and ribavirin were purchased from Virazole, October Pharma, Cairo. Bax, P53 and TGF- β primary antibodies and secondary antibodies for immunohistochemical studies and western blot analysis were purchased from Santa Cruz Biotechnology, CA.

Plant materials & extract preparation

Jerusalem artichoke tubers were kindly gifted from Dr/ Abdel Badea Saleh Ezzat and Dr/ Amal Abou-El Fotouh E-Awady, Assistant Professors of Agriculture, Vegetable Research Department, Horticulture Research Institute, Agricultural Research Centre, Cairo, Egypt. The tubers were cultivated, identified and preserved under their supervision. A voucher specimen was deposited in Agricultural Research Centre Herbarium, Cairo, Egypt.. JAT was washed and sliced individually to a thickness of approximately 1mm. Artichoke slices were then soaked in lemon juice combined with citric acid and ascorbic acid in order to inhibit polyphenol oxidase activity. Thereafter were subjected to dryness process by solar energy, blended, packed and frozen at -80 °C (Zawistowski et al., 1986).

Animals and experimental design

Male albino rats (150-200g) were purchased from the animal house colony, National Research Centre, Giza. The animals were housed under standardized environmental conditions, fed with standard diet and libitum during the entire period of experimentation, and left to acclimatize to the environment for one week prior to inclusion in the experiment at 22 °C $\pm$ 2 °C under a 12/12 hrs light/dark cycle. All animal experiments were submitted to and approved by Faculty of Pharmacy, Minia university research ethics committee and were conducted

in accordance with the guide for the care and use of laboratory animals of the National Institute of Health (NIH publication No. 85-23, revised 1985).

Animals were divided randomly into 12 groups (20 rats each) as follows: **Group I:** untreated normal healthy group received only olive oil for the whole period of experiment (8 weeks). **Group II:** rats received only JAT orally (1g/kg body weight daily)(EA, 2009). **Group III:** rats received only peginterferon-alpha intraperitoneally (1.5 μ g/kg per week)(Tasci et al., 2007). **Group IV:** rats received only ribavirin orally (60 mg/kg daily)(Solbrig et al., 2002). **Group V:** rats received peginterferon-alpha and ribavirin. **Group VI:** rats received triple treatment of JAT, peginterferon-alpha and ribavirin. **Group VII:** hepatic fibrosis was induced by treating rats by gavage with CCl₄-olive oil (1:1, 2.8 ml/kg followed by 1.4 ml/kg after one week)(Abdel Salam et al., 2007). **Group VIII:** rats received JAT starting from day one of CCl₄ treatment. **Group IX:** Rats received peginterferon-alpha starting from day one of CCl₄ treatment. **Group X:** Rats received ribavirin starting from day one of CCl₄ treatment. **Group XI:** Rats received peginterferon-alpha and ribavirin starting from day one of CCl₄ treatment. **Group XII:** Rats received triple treatment of JAT, ribavirin and peginterferon-alpha starting from day one of CCl₄ treatment. All animals were sacrificed after 8 weeks of CCL₄-treatment.

Sample preparations

Blood samples were withdrawn along the experiment after an overnight fast from retro-orbital venus plexus each week. At the end of the experiment, the blood was withdrawn from the carotid vein by cutting with fine scissors. The blood was collected by dripping into non-EDTA containing test tube. Serum was separated by centrifugation for 15 minutes at 3000 xg. Samples were then stored in aliquots in eppendorf tubes and frozen at -80 °C.

Biochemical analysis

Serum ALT and AST activities were measured by the dinitrophenylhydrazene method according to Reitman and Frankel (Reitman and Frankel, 1957). Colorimetric determination of serum bilirubin was done as described previously (Watson and Rogers, 1961).

Histopathological investigation

Liver slices were fixed in 10% formaldehyde and embedded in paraffin wax blocks. Sections of 5 μ m thick were stained with hematoxylin and eosin (H&E), and Masson trichrom stain then examined under light microscope for determination of pathological changes. The histological evaluation of the hepatic injury was semi-quantitatively scored by two independent observers who undertook the evaluation using an ocular micrometer by light microscopy. The severity of the hepatic injury was scored viz. (-) no injury; (+) mild; (++) moderate, and (+++) severe. The examination of the hepatic injury consisted of the evaluation of the following: vena centralis, portal area, and sinusoidal congestion, ballooning degeneration of hepatocytes and

its location, the presence of focal parenchymal necrosis, Polymorphonuclear leukocytes (PMNL) infiltration and mononuclear leukocytes (MNL) infiltration, karyolysis of hepatocyte nuclei, the presence of pyknosis, loss of intercellular borders and disintegration of hepatic cords. Assessment of hepatic fibrosis was performed using semiquantitative fibrosis scores. Healthy liver was classified as 0. Fibrous expansion of the portal areas was scored as 1. Stage 2 denotes septal fibrosis with marked fibrous septa, and stage 3 was characterized by portal-portal septa (bridging fibrosis but intact architecture). The advanced fibrotic stage 4 (i.e., cirrhosis) is characterized by bridging fibrosis with nodules (Roderfeld et al., 2006a; Roderfeld et al., 2006b).

Immunohistochemical analysis of Bax, P53 & TGF- β

Liver tissue sections were subjected to dewaxing, hydration and thermal induction antigen retrieval. Slices were blocked and incubated with anti-Bax antibody (1:200), anti-p53 antibody (1:100), and anti-TGF- β antibody (1:200) which were diluted in phosphate buffered

saline solution and incubated at 4°C overnight. The following day, tissue slices were washed and incubated with secondary antibodies. The slices were then incubated with diaminobenzidine tetrachloride for 5-10 minutes to develop colour, and staining was observed under microscope (CR, 1994).

Western Blot analysis of Bax, P53 and TGF- β

Proteins were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes (Millipore). The membranes were blocked with 5% BSA for 2 h, and then incubated overnight at 4°C with anti-Bax antibody (1:200), anti-p53 antibody (1:100), and anti-TGF- β antibody (1:200). The membranes were then incubated with HRP-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (1:5000) at room temperature for 2 h, and then washed again and detected by the enhanced chemiluminescence reaction (Towbin et al., 1979). The intensities of the bands were then analyzed with Image J software.

Table 1. Liver Function Tests for Different Experimental Groups in the Study

	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	P value
ALT $\pm$ SD (IU/L)	30.8 $\pm$ 2.89	32.7 $\pm$ 0.82	30.2 $\pm$ 2.56	32.0 $\pm$ 0.89	32.3 $\pm$ 1.08	30.2 $\pm$ 0.98	141 $\pm$ 1.47	91.7 $\pm$ 5.49	83.7 $\pm$ 1.63	56.2 $\pm$ 1.57	41.9 $\pm$ 2.06	36.2 $\pm$ 1.47	<0.01
AST $\pm$ SD (IU/L)	22.5 $\pm$ 2.26	22.6 $\pm$ 1.11	22.6 $\pm$ 1.11	22.7 $\pm$ 1.99	22.8 $\pm$ 1.72	24.7 $\pm$ 1.47	92.5 $\pm$ 1.52	75.2 $\pm$ 1.52	45.8 $\pm$ 1.33	64.8 $\pm$ 1.6	46.0 $\pm$ 1.67	31.7 $\pm$ 1.47	<0.01
Bilirubin $\pm$ SD (mg/dl)	0.44 $\pm$ 0.09	0.48 $\pm$ 0.05	0.43 $\pm$ 0.04	0.5 $\pm$ 0.04	0.41 $\pm$ 0.05	0.40 $\pm$ 0.04	1.9 $\pm$ 0.48	1.05 $\pm$ 0.06	1.1 $\pm$ 0.06	1.2 $\pm$ 0.11	1.08 $\pm$ 0.09	0.69 $\pm$ 0.05	<0.01

Data are expressed as X $\pm$ SD of 20 rats in each group (n=20). Significant difference between groups was analyzed by t-Student test, where P < 0.05 is considered significant.

Table 2. Histopathological Evaluation for Different Experimental Groups in the Study

Group	Congestion			PMNL			MNL		
	Central vein	Portal space	Sinusoid	Central vein	Portal space	Sinusoid	Central vein	Portal space	Sinusoid
Control	-	-	-	-	-	-	-	-	-
CCl4	+++	+++	+++	-	+	-	+	+++	++
Artichoke	++	+++	++	-	-	-	-	++	+
ribavirin	++	+++	++	-	-	-	+	+++	++
Interferon	+	+	+	-	-	-	+	++	-
Interferon and ribavirin	+	+	+	-	-	-	+	++	-
Interferon, ribavirin and artichoke	-	+	-	-	-	-	-	+	-
	Ballooning degeneration and localisation		Necrosis	Karyolysis and pyknosis		Loss of intercellular borders	Disintegration of hepatic cords		
Control	-		-	-		-	-		
CCl4	+++CL	++MZ	+++	++		+++	+++		
Artichoke	+CL	-MZ	+	++		+	++		
ribavirin	++CL	++MZ	++	++		++	++		
Interferon	+CL	-MZ	+	++		+	+		
Interferon and ribavirin	+CL	-MZ	-	+		+	+		
Interferon, ribavirin and artichoke	-CL	-MZ	-	+		+	-		

The severity of the hepatic injury was scored viz. (-), no injury; (+), mild; (++) moderate, and (+++) severe. The examination of the hepatic injury consisted of the evaluation of the following: vena centralis, portal area, and sinusoidal congestion, ballooning degeneration of hepatocytes and its location, the presence of focal parenchymal necrosis, Polymorphonuclear leukocytes (PMNL) infiltration and mononuclear leukocytes (MNL)

Statistical analysis

Data were estimated using analysis of variance and all values were expressed as mean± SD. P-value < 0.05 was considered significant. All analyses were implemented by SPSS 20 software for windows (Chicago IL, United States).

Results

Liver toxicity studies for JAT, interferon and ribavirin

Six groups of rats were administered the same dose of JAT, interferon, and ribavirin without intoxication with CCl₄. Liver biomarkers were then measured (Table 1). Our data showed that the used doses in our experiment were safe and comparable to control healthy group.

Effect of JAT and other combinations on serum biomarkers of hepatic injury induced by CCl₄

ALT,AST activities and bilirubin levels were markedly increased in CCl₄- intoxicated group compared to the normal healthy group, which were significantly lowered by administration of JAT in combination with interferon and ribavirin (p < 0.01).

JAT in combination with interferon and ribavirin attenuates hepatic fibrosis

Following 8 weeks of CCl₄ administration, liver histopathology was significantly changed in the CCl₄ group. The livers showed moderate to marked congestion

Figure 1. Histopathological Analysis for the Effect of Different Treatment Combinations on Hepatic Damage using H&E and Masson Trichrome Stains. A. Normal untreated control 1. Normal architecture. 2. No fibrosis, no fatty change B. CCl₄ group: 3. Black arrow showing marked fibrosis. 4. Marked fatty change (black arrow), marked inflammation (red arrow). H&E stain. 5. Showing marked sinusoidal congestion (black arrow). 6. Marked congestion (black arrow), marked desintegration of hepatic cords (red arrow). Hepatocyte necrosis (red arrow head; H&E stain). C. CCl₄ + Interferon group: 7. Mild central venous congestion (black arrow). Mild sinusoidal congestion (red arrow). H&E stain. 8. Mild fatty change (black arrow). Mild sinusoidal congestion (red arrow). H&E stain. D. CCl₄ and Ribavirin group: 9. Marked congestion in portal tract (black arrow). H&E stain. E. Interferon and ribavirin group. 10. Mild sinusoidal congestion (black arrow). H&E stain. F triple 11. Mild portal tract inflammation (black arrow), preserved hepatic cords. H&E stain. 12. Mild inflammatory cellular infiltrate of portal tract. H&E stain

in the central vein and severe congestion in the portal area and sinusoids. Parenchymal necrosis was observed.

Figure 2. Immunohistochemical Analysis of TGF-β, Bax, P53 in liver tissue of different experimental Groups. A. Normal untreated control B. CCl₄ group C. CCl₄ intoxicated group treated with Interferon D. CCl₄ intoxicated group treated with Ribavirin E. CCl₄ intoxicated group treated with Interferon and Ribavirin F. CCl₄ intoxicated group treated with Interferon, Ribavirin and JAT.

Figure 3. Western Blotting for P53, Bax, and TGF-β Proteins in Liver Homogenate. 1. Normal untreated control 2,3, and 4. CCl₄ group 5. CCl₄ intoxicated group treated with Interferon 6. CCl₄ intoxicated group treated with Artichoke 7. CCl₄ intoxicated group treated with Ribavirin 8. CCl₄ intoxicated group treated with Interferon and Ribavirin 9. CCl₄ intoxicated group treated with Interferon, Ribavirin and JAT. β-actin acted as loading control to ensure even loading

Polymorphonuclear leukocytes (PMNL) infiltration was mild whereas mononuclear leukocytes (MNL) infiltration was mild in the central vein, severe in the portal area and moderate in the sinusoids. Moderate karyolysis and pyknosis, and severe loss of intracellular borders and disintegration of hepatic cords were observed. In the groups treated by single agent; JAT, interferon or ribavirin alone with CCl₄, livers appeared to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. However, hepatocytes from rats treated with triple combination of interferon, ribavirin, and JAT showed more or less normal appearance.

Effect of JAT on hepatic protein expression of P53, TGF- β and Bax

We further examined effect of various agents on TGF- β and Bax protein expression, as shown in Figure 2 and 3, the expression levels of the pro-apoptotic protein, Bax, and TGF- β were increased in CCl₄ group. In contrast, groups treated with JAT, Peg-interferon and ribavirin separately or in combination showed reduction in the expression of TGF- β and Bax. The lowest level of expression was observed in the triplet combination. Hepatic protein expression of p53 was also significantly higher in CCl₄-intoxicated group compared to other groups as detected by immunohistochemical staining. P53 immunopositive cells reached up to 70% of the stained area compared to 5% observed in the negative control group. Moreover, CCl₄ treatment caused cytoplasmic translocation of p53 protein. In the group treated by triple combination of interferon, ribavirin, and JAT, the expression level of p53 was markedly reduced. This is consistent with our western blotting analysis which showed that p53 protein expression was enhanced in CCl₄-treated group and significantly reduced with the triplet-treatment.

Discussion

Most chronic liver disorders are associated with fibrosis which is a process of excessive accumulation of extracellular matrix proteins in the liver (Bataller and Brenner, 2005). This process may lead to damage of the original hepatic architecture. Severe form of liver fibrosis may eventually progress to hepatocellular carcinoma (Castilla et al., 1991; Baldo et al., 2008; Schuppan and Afdhal, 2008).

Several studies have demonstrated the anti-fibrogenic effect of interferon (Muriel, 1996) via inhibiting TGF- β expression (Castilla et al., 1991; Tsushima et al., 1999; Chang et al., 2005), which decreases hepatic stellate cell activation and stimulates apoptosis (Chang et al., 2005). In the current study we demonstrate that the co-administration of JAT along with interferon and ribavirin can revert liver fibrosis more effectively.

CCl₄ intoxication is the best known experimental model for liver injury so far. CCl₄ administration can induce chronic liver damage in rats. It is metabolized by cytochrome P450 system to highly reactive trichloromethyl free radicals, which initiate liver cell destruction (McCay et al., 1984; Brattin et al., 1985). As previously reported,

administration of CCl₄ for 8 weeks resulted in a significant increase in serum ALT, AST activities as well as total bilirubin levels (Mehmetcik et al., 2008; Arici and Cetin, 2011). Damaged liver architecture can lead to an increase in the serum activities of liver enzymes due to their localization in the cytoplasmic area of the cell (Althnaian et al., 2013). These biomarkers showed major improvement to near normal values with triplet combination, which is an indication of the stabilization of the plasma membrane and the repair of hepatic tissue damage caused by CCl₄ intoxication. A previous study showed a significant decrease in serum ALT activities of diabetic rats fed on JAT (Aslan et al., 2010).

In the present study, Liver sections of animals intoxicated with CCl₄ showed centrilobular congestion and ballooning degeneration, vacuolization and necrosis with loss of hepatocytes, leading to disintegration of hepatic cords with fibrosis as well as massive necrosis, accompanied with microvesicular steatosis and mononuclear cellular infiltration. Moreover, Masson's trichrome stain of liver sections showed congestion and thickening of the portal tract with dense fibrous tissue. Similar observations of the liver tissues in CCl₄ intoxicated rats were reported previously (Domitrovic et al., 2009; Althnaian et al., 2013).

P53 gene is a major well studied tumor suppressor gene. It has been reported before to be inactivated in most cancers (Helm et al., 1999; Vogelstein et al., 2000). P53 protein was reported to inhibit cellular division in stressed cells. Alternatively, p53 causes these stressed cells to undergo apoptosis (Helm et al., 1999). It is still unclear what other roles are played by p53. Importantly, it was shown before that p53 is involved in the molecular mechanisms leading to liver injuries (Blight et al., 2003; Schafer et al., 2003). Indeed, patients with various inflammatory liver diseases were found to accumulate p53 protein (Akyol et al., 1999; Panasiuk et al., 2006; Attallah et al., 2009). It has been also reported that p53 serum level was elevated in HBV-related cirrhosis patients (Shahnazari et al., 2014). In line with these reports, we could show that the level of p53 was significantly higher in the livers of rats intoxicated with CCl₄ compared to normal control as detected by immunohistochemical staining. The triple combination was able to successfully diminish the elevated expression level of p53 protein. One possible explanation for the elevated p53 level may be the reduction of p53 protein breakdown, leading to the accumulation of p53 protein. Another possibility is that p53 gene is modulated enhancing p53 synthesis (Papakyriakou et al., 2002; Panasiuk et al., 2006).

P53 protein can cause apoptosis through different p53-regulated pathways such as p21, and Bax for example (Vousden and Lu, 2002). BAX is a pro-apoptotic protein. Its expression level was previously shown to elevate following to an apoptotic stimulus (Green, 2000). The increment in the BAX expression level leads to caspase-3 activation, with consequent cell death (Hengartner, 2000; Panasiuk et al., 2006; Ramalho et al., 2006). We were able to show that the expression level of the pro-apoptotic protein, Bax, was increased in CCl₄ group. This was in accordance with previous reports (Tsamandas et

al., 2003; Guo et al., 2013) which reported that Bax was over regulated in advanced fibrotic stages. Our results demonstrated that the triple combination was more effective in suppression of p53 and Bax expression levels compared to any single treatment. This finding suggests that the triple combination can attenuate CCl₄-induced hepatocyte apoptosis via a p53-mediated pathway and can retard the progression of liver fibrosis induced by CCl₄ in rats.

Our results also showed similar hepatic expression patterns for TGF- β . Liver fibrosis usually leads to the development of irreversible cirrhosis if untreated (Riley and Bhatti, 2001). It was reported before that hepatocellular damage stimulates inflammatory cells which eventually lead to activation of hepatic stellate cells. Activated hepatic stellate cells produce large amounts of extracellular matrix proteins and thereby enhance fibrosis. This happens due to secreting a broad spectrum of cytokines such as TGF- β 1 which exerts pro-fibrotic actions (Xu et al., 2004). Indeed, one of the key mediators in liver fibrogenesis is the growth factor, TGF- β . It has been reported before that the inhibition of TGF- β synthesis significantly suppresses liver fibrosis development (Lotersztajn et al., 2005).

In conclusion, addition of JAT to the classical anti-fibrogenic regimen (interferon and/or ribavirin) can effectively improve their curative potential.

Acknowledgements

Authors are grateful to Prof. Salwa Gaber and Dr. Mona Osman Department of Pathology, Faculty of Medicine, Minia University for their assistance in the histopathological study. The authors declare that no conflict of interests exists. Nabil Mohie Abdel-Hamid, proposed the idea of the study and participated in paper revision. Ahmed Wahid participated in selection of study design, animal handling, biochemical analysis, western blotting analysis, paper writing and submission. Maiiada Hassan Nazmy participated in selection of study design, animal handling, biochemical analysis, western blotting analysis and paper revision. Marwa Abdel-Moniem Eisa participated in animal handling, biochemical analysis and western blotting analysis.

References

- Abdel Salam OM, Sleem AA, Omara EA, et al (2007). Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats. *Drug Target Insights*, **2**, 19-27.
- Abdel-Hamid NM, Nazmy MH, Mahmoud AW, et al (2011). A survey on herbal management of hepatocellular carcinoma. *World J Hepatol*, **3**, 175-83.
- Abdel-Hamid NM, Nazmy MH, Wahid A, et al (2015). Jerusalem artichoke attenuates experimental hepatic fibrosis via modulation of apoptotic signaling and fibrogenic activity. *Biochemistry Biotechnol Res*, **3**, 43-50.
- Aithal GP, Watkins PB, Andrade RJ, et al (2011). Case definition and phenotype standardization in drug-induced liver injury. *Clin Pharmacol Ther*, **89**, 806-15.
- Akyol G, Dursun A, Poyraz A, et al (1999). P53 and proliferating cell nuclear antigen (PCNA) expression in non-tumoral liver diseases. *Pathol Int*, **49**, 214-21.
- Althnaian T, Albokhadaim I, El-Bahr SM (2013). Biochemical and histopathological study in rats intoxicated with carbontetrachloride and treated with camel milk. *Springerplus*, **2**, 57.
- Arici OF, Cetin N (2011). Protective role of ghrelin against carbon tetrachloride (CCl₄)-induced coagulation disturbances in rats. *Regul Pept*, **166**, 139-42.
- Aslan M, Orhan N, Orhan DD, et al (2010). Hypoglycemic activity and antioxidant potential of some medicinal plants traditionally used in Turkey for diabetes. *J Ethnopharmacol*, **128**, 384-9.
- Attallah AM, Shiha GE, Ismail H, et al (2009). Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. *Clin Biochem*, **42**, 455-61.
- Baldo V, Baldovin T, Trivello R, et al (2008). Epidemiology of HCV infection. *Curr Pharm Des*, **14**, 1646-54.
- Bataller R, Brenner DA (2005). Liver fibrosis. *J Clin Invest*, **115**, 209-18.
- Blight KJ, McKeating JA, Marcotrigiano J, et al (2003). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *J Virol*, **77**, 3181-90.
- Boigk G, Stroedter L, Herbst H, et al (1997). Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. *Hepatology*, **26**, 643-9.
- Brattin WJ, Glende EA, Jr., Recknagel RO (1985). Pathological mechanisms in carbon tetrachloride hepatotoxicity. *J Free Radic Biol Med*, **1**, 27-38.
- Castilla A, Prieto J, Fausto N (1991). Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. *N Engl J Med*, **324**, 933-40.
- Chang WC, Jia H, Aw W, et al (2014). Beneficial effects of soluble dietary Jerusalem artichoke (*Helianthus tuberosus*) in the prevention of the onset of type 2 diabetes and non-alcoholic fatty liver disease in high-fructose diet-fed rats. *Br J Nutr*, **112**, 709-17.
- Chang XM, Chang Y, Jia A (2005). Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. *World J Gastroenterol*, **11**, 2634-6.
- CR T (1994). The current role of immunohistochemistry in diagnostic pathology. *Adv Pathol Lab Med*, **7**.
- Domitrovic R, Jakovac H, Tomac J, et al (2009). Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. *Toxicol Appl Pharmacol*, **241**, 311-21.
- EA Z (2009). Physiological response to diets fortified with Jerusalem artichoke tubers (*Helianthus tuberosus* L.) powder by diabetic rats. *American-Eurasian J Agric Environ Sci*, **5**, 682-8.
- Fujii H, Nishimura T, Umemura A, et al (2015). Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. *World J Hepatol*, **7**, 2841-8.
- Gao B, Bataller R (2011). Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterol*, **141**, 1572-85.
- Gebhardt R (2002). Oxidative stress, plant-derived antioxidants and liver fibrosis. *Planta Med*, **68**, 289-96.
- Green DR (2000). Apoptotic pathways: paper wraps stone blunts scissors. *Cell*, **102**, 1-4.
- Guo XL, Liang B, Wang XW, et al (2013). Glycyrrhizic acid attenuates CCl₄-induced hepatocyte apoptosis in rats via a p53-mediated pathway. *World J Gastroenterol*, **19**, 3781-91.
- Helm M, Brule H, Giege R, et al (1999). More mistakes by T7 RNA polymerase at the 5' ends of *in vitro*-transcribed RNAs. *RNA*, **5**, 618-21.

- Hengartner MO (2000). The biochemistry of apoptosis. *Nature*, **407**, 770-6.
- Kucukgergin C, Aydin AF, Ozdemirler-Erata G, et al (2010). Effect of artichoke leaf extract on hepatic and cardiac oxidative stress in rats fed on high cholesterol diet. *Biol Trace Elem Res*, **135**, 264-74.
- Lotersztajn S, Julien B, Teixeira-Clerc F, et al (2005). Hepatic fibrosis: molecular mechanisms and drug targets. *Annu Rev Pharmacol Toxicol*, **45**, 605-28.
- Mayo MJ (2011). Management of autoimmune hepatitis. *Curr Opin Gastroenterol*, **27**, 224-30.
- McCay PB, Lai EK, Poyer JL, et al (1984). Oxygen- and carbon-centered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals *in vivo* and *in vitro*. *J Biol Chem*, **259**, 2135-43.
- Mehmetcik G, Ozdemirler G, Kocak-Toker N, et al (2008). Role of carnosine in preventing thioacetamide-induced liver injury in the rat. *Peptides*, **29**, 425-9.
- Minano C, Garcia-Tsao G (2010). Clinical pharmacology of portal hypertension. *Gastroenterol Clin North Am*, **39**, 681-95.
- Muriel P (1996). Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in the rat. *J Hepatol*, **24**, 614-21.
- Nobili V, Carter-Kent C, Feldstein AE (2011). The role of lifestyle changes in the management of chronic liver disease. *BMC Med*, **9**, 70.
- Panasiuk A, Dzieciol J, Panasiuk B, et al (2006). Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. *World J Gastroenterol*, **12**, 6198-202.
- Papakyriakou P, Tzardi M, Valatas V, et al (2002). Apoptosis and apoptosis related proteins in chronic viral liver disease. *Apoptosis*, **7**, 133-41.
- Punzi R, Paradiso A, Fasciano C, et al (2014). Phenols and antioxidant activity *in vitro* and *in vivo* of aqueous extracts obtained by ultrasound-assisted extraction from artichoke by-products. *Nat Prod Commun*, **9**, 1315-8.
- Ramalho RM, Cortez-Pinto H, Castro RE, et al (2006). Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. *Eur J Gastroenterol Hepatol*, **18**, 21-9.
- Reitman S, Frankel S (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol*, **28**, 56-63.
- Riley TR, 3rd, Bhatti AM (2001). Preventive strategies in chronic liver disease: part II. Cirrhosis. *Am Fam Physician*, **64**, 1735-40.
- Roberfroid MB, Delzenne NM (1998). Dietary fructans. *Annu Rev Nutr*, **18**, 117-43.
- Roberfroid MB, Van Loo JA, Gibson GR (1998). The bifidogenic nature of chicory inulin and its hydrolysis products. *J Nutr*, **128**, 11-9.
- Roderfeld M, Geier A, Dietrich CG, et al (2006a). Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. *Liver Int*, **26**, 579-86.
- Roderfeld M, Weiskirchen R, Wagner S, et al (2006b). Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. *FASEB J*, **20**, 444-54.
- Sakaida I, Tsuchiya M, Kawaguchi K, et al (2003). Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. *J Hepatol*, **38**, 762-9.
- Schafer T, Scheuer C, Roemer K, et al (2003). Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. *FASEB J*, **17**, 660-7.
- Schuppan D, Afdhal NH (2008). Liver cirrhosis. *Lancet*, **371**, 838-51.
- Schuppan D, Jia JD, Brinkhaus B, et al (1999). Herbal products for liver diseases: a therapeutic challenge for the new millennium. *Hepatology*, **30**, 1099-104.
- Serni E, Audino V, Del Carlo S, et al (2013). Determination of water-soluble vitamins in multivitamin dietary supplements and in artichokes by micellar electrokinetic chromatography. *Nat Prod Res*, **27**, 2212-5.
- Shahnazari P, Sayehmiri K, Minuchehr Z, et al (2014). The increased level of serum p53 in hepatitis b-associated liver cirrhosis. *Iran J Med Sci*, **39**, 446-51.
- Solbrig MV, Schlager R, Briese T, et al (2002). Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. *Antimicrob Agents Chemother*, **46**, 2287-91.
- Tasci I, Mas MR, Vural SA, et al (2007). Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. *World J Gastroenterol*, **13**, 3237-44.
- Thursz M, Yee L, Khakoo S (2011). Understanding the host genetics of chronic hepatitis B and C. *Semin Liver Dis*, **31**, 115-27.
- Towbin H, Staehelin T, Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A*, **76**, 4350-4.
- Tsamandas AC, Thomopoulos K, Zolota V, et al (2003). Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. *Mod Pathol*, **16**, 1273-88.
- Tsushima H, Kawata S, Tamura S, et al (1999). Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. *J Hepatol*, **30**, 1-7.
- Veillon P, Fouchard-Hubert I, Larrey D, et al (2015). Does epoetin beta still have a place in peginterferon alpha-2a plus ribavirin treatment strategies for chronic hepatitis c? *J Interferon Cytokine Res*.
- Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. *Nature*, **408**, 307-10.
- Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. *Nat Rev Cancer*, **2**, 594-604.
- Watson D, Rogers JA (1961). A study of six representative methods of plasma bilirubin analysis. *J Clin Pathol*, **14**, 271-8.
- Xu XB, Leng XS, Yang X, et al (2004). Obstruction of TGF-beta1 signal transduction can decrease the process of hepatocellular carcinoma in mice induced by CCl₄/ethanol. *Zhonghua Yi Xue Za Zhi*, **84**, 1122-5 (in Chinese).
- Zawistowski J, Blank G, Murray ED (1986). Polyphenol oxidase activity in Jerusalem artichokes (*Helianthus tuberosus* L.). *Can Institute Food Science Technol J*, **19**, 210-4.